FindTrial
Sign In

V501

BIOLOGICAL6 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Adenocarcinoma in SituAnogenital Human Papilloma Virus InfectionCervical CancerCervical Intraepithelial NeoplasiaCondyloma AcuminataGenital WartsHumanPapillomavirus Infections

Phase 3

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
CompletedNCT00092521
Merck Sharp & Dohme LLCCervical Cancer, Genital Warts
Start: 2001-12-31End: 2009-01-31Updated: 2015-09-25
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
CompletedNCT00092547
Merck Sharp & Dohme LLCHuman, Papillomavirus Infections
Start: 2003-10-08End: 2015-06-01Updated: 2018-02-20
Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)
CompletedNCT01862874
Merck Sharp & Dohme LLCAnogenital Human Papilloma Virus Infection, Condyloma Acuminata
Start: 2013-06-27End: 2017-08-30Updated: 2019-04-02
Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
CompletedNCT02576054
Merck Sharp & Dohme LLCAnogenital Human Papilloma Virus Infection, Condyloma Acuminata
Start: 2015-11-20End: 2018-08-08Updated: 2019-11-25
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
CompletedNCT03493542
Merck Sharp & Dohme LLCPrevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
Start: 2018-08-31End: 2023-10-30Updated: 2024-12-31

Phase 4

V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
CompletedNCT01544478
Merck Sharp & Dohme LLCAdenocarcinoma in Situ, Cervical Cancer, Cervical Intraepithelial Neoplasia
Start: 2011-11-25End: 2016-08-27Updated: 2018-11-28

Related Papers

Effect of Prior 9-Valent Human Papillomavirus Vaccination on Subsequent Lower Genital Tract Dysplasia After Cervical Excisional Surgery.
2025-10-301 citations
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
2020-11-223 citations
Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology
BMJ evidence-based medicine2020-03-179 citations
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population
Gynecologic Oncology2019-04-1190 citations
Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women
Journal of Infection and Chemotherapy2019-03-157 citations
Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study
Vaccine2019-02-2054 citations
Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study
Japanese Journal of Infectious Diseases2019-01-014 citations
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15–26 Years of Age
Obstetrics and Gynecology2018-07-1137 citations
Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease.
2012-10-1211 citations
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
2012-03-27196 citations
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia.
2011-04-0656 citations
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
2010-07-20260 citations
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.
2009-12-0179 citations
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
2009-04-01414 citations
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
2009-04-01189 citations
Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.
2008-01-013 citations
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.
2007-12-0548 citations
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
2007-06-01375 citations
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
2007-05-011224 citations